Global Viral Disease Diagnosis Market Overview
As per MRFR analysis, the Viral Disease Diagnosis Market Size was estimated at 8.87 (USD Billion) in 2023. The Viral Disease Diagnosis Market Industry is expected to grow from 9.37 (USD Billion) in 2024 to 14.69 (USD Billion) by 2032. The Viral Disease Diagnosis Market CAGR (growth rate) is expected to be around 5.78% during the forecast period (2024 - 2032).
Key Viral Disease Diagnosis Market Trends Highlighted
The viral disease diagnosis market is experiencing a surge in demand due to increasing incidences of viral infections and the ongoing COVID-19 pandemic.
Advancements in diagnostic technologies, such as multiplex PCR and next-generation sequencing, are enhancing accuracy and reducing turnaround time, driving market growth.
Furthermore, the rise of point-of-care testing devices and home-based sampling is expanding access to testing, particularly in resource-limited settings.
Growing awareness and public health initiatives are also contributing to market expansion. Recent trends include the incorporation of artificial intelligence and machine learning algorithms for improved diagnostic accuracy and personalized medicine approaches.
Emerging technologies like biosensors and nanotechnology hold promise for further advancements in viral disease diagnosis, creating opportunities for market innovation and expansion.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Viral Disease Diagnosis Market Drivers
Rising Prevalence of Viral Diseases
Millions of people worldwide are affected by the viral disease and it’s one of the main concerns for global health.
The rise in the prevalence of viral diseases such as influenza, HIV, hepatitis, and others is a key driver of the growth of the Viral disease diagnosis market.
The demand for accurate and quick diagnosis has increased due to the rapid increase in the number of viral diseases, resulting in market growth.
Technological Advancements in Viral Diagnostics
The Viral disease diagnosis market is witnessing significant growth due to the rapid advancements in viral diagnostics.
The development of new technologies, such as molecular diagnostics, point-of-care testing, and multiplex assays, has revolutionized the diagnosis of viral diseases.
These technologies offer improved accuracy, speed, and convenience, which is driving their adoption in clinical settings.
Increased Healthcare Expenditure
Another huge driver for the growth of the viral disease diagnosis market is the increasing healthcare expenditure around the world.
Governments and healthcare organizations are investing millions of dollars in the improvement and development of healthcare facilities and diagnostic technologies.
This development in technology due to funding is leading to a rise in the introduction of new and innovative diagnostic options which are supporting the growth of the industry.
Viral Disease Diagnosis Market Segment Insights:
Viral Disease Diagnosis Market Disease Type Insights
The viral disease diagnosis market is segmented by the type of disease into HIV, Hepatitis, Influenza, RSV, CMV, EBV, and HSV. The HIV segment was the largest segment of the viral disease diagnosis market, and it is expected to remain the largest segment during the forecast period.
This is due to the high prevalence of HIV infection, as well as the availability of advanced diagnostic tests. The Hepatitis segment is expected to grow the fastest during the forecast period. Hepatitis B and C infections are increasingly prevalent, driving the demand for early diagnosis and monitoring.
The Influenza segment is also expected to grow steadily, owing to the seasonal nature of the disease and the need for rapid and accurate diagnosis. The RSV segment is expected to grow at a moderate pace as the incidence of RSV infection in infants and young children is increasing, along with the presence of effective diagnosis. The CMV segment is expected to grow at a steady pace.
The high incidence of CMV infection in immunocompromised patients is boosting the demand for molecular diagnostic tests. The EBV segment is expected to grow moderately due to the increasing incidence of EBV infection in the general population, along with the availability of serological and molecular tests for diagnosis.
The HSV segment is expected to grow steadily as well, due to the high prevalence of HSV infection and the availability of rapid and accurate diagnostic tests.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Viral Disease Diagnosis Market Specimen Type Insights
The Viral disease diagnosis market is segmented by Specimen Type into Blood, Urine, Saliva, Swabs, Sputum, Stool, and Others. Blood is the most commonly used specimen type for viral disease diagnosis due to its accessibility and the presence of various biomarkers in the blood that can indicate a viral infection.
Urine and Saliva are also commonly used specimen types, particularly for the diagnosis of respiratory viruses. Swabs are used to collect samples from the respiratory tract or other mucosal surfaces, while Sputum is collected from the lungs.
The stool is used to diagnose gastrointestinal viral infections. The Blood segment accounted for the largest share of the Viral disease diagnosis market in 2023 and is expected to continue to dominate the market over the forecast period.
The Urine and Saliva segments are expected to experience significant growth due to the increasing use of non-invasive diagnostic methods. The Swabs segment is also expected to grow due to the rising prevalence of respiratory viral infections.
Overall, the Specimen Type segment of the Viral disease diagnosis market is expected to grow at a substantial CAGR during the forecast period, driven by the increasing prevalence of viral diseases, the development of new diagnostic technologies, and the growing demand for accurate and timely diagnosis.
Viral Disease Diagnosis Market Technology Insights
Immunoassays are another widely used technology, as they are relatively inexpensive and easy to perform. Serology tests are used to detect antibodies against a specific virus and can be used to diagnose both acute and chronic infections.
Molecular diagnostics is a newer technology that uses molecular markers to identify viruses and is becoming increasingly popular due to their high accuracy and sensitivity. Rapid diagnostic tests are used to provide a quick and convenient diagnosis of viral infections and are often used in point-of-care settings.
Viral Disease Diagnosis Market Application Insights
The Viral disease diagnosis market is segmented based on application into Diagnostics, Surveillance, Treatment Monitoring, and Prognosis.
Among these segments, Diagnostics is expected to hold the largest market share in 2023, owing to the increasing prevalence of viral diseases and the need for early and accurate diagnosis. The market for Surveillance is also expected to grow significantly due to the increasing need for monitoring viral outbreaks and tracking the spread of new and emerging viruses.
Treatment Monitoring and Prognosis segments are expected to witness steady growth due to the increasing demand for personalized and targeted therapies for viral diseases.
The Viral disease diagnosis market is expected to reach a valuation of USD 34.56 Billion by 2024, exhibiting a CAGR of 10.5% during the forecast period of 2024-2032
Viral Disease Diagnosis Market End User Insights
The end user segment of the viral disease diagnosis market plays a crucial role in driving market growth. Hospitals are expected to hold a significant market share due to the increasing prevalence of viral diseases and the rising number of hospitalizations.
Clinics are also expected to contribute to market growth as they offer convenient and accessible diagnostic services. Laboratories are another key segment, as they provide specialized testing services for viral diseases.
Research institutions are also expected to contribute to market growth as they conduct research and development activities for new diagnostic technologies.
Public health agencies are also expected to play a significant role in the market as they implement surveillance and prevention programs for viral diseases.
Viral Disease Diagnosis Market Regional Insights
The Viral disease diagnosis market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East and Africa. North America is the largest regional segment, accounting for over 40% of the global market in 2023.
The region is home to a large number of pharmaceutical and biotechnology companies, as well as a well-developed healthcare infrastructure. Europe is the second-largest regional segment, with a market share of over 30%. The region has a strong tradition of medical research and development and is home to a number of leading academic and research institutions.
Asia Pacific is the fastest-growing regional segment, with a market share of over 20%. The region is home to a large and growing population, as well as a rapidly developing healthcare sector.
South America and the Middle East and Africa are the smallest regional segments, with market shares of less than 10%. However, these regions are expected to experience significant growth in the coming years, due to increasing healthcare spending and a growing awareness of viral diseases.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Viral Disease Diagnosis Market Key Players and Competitive Insights:
The major companies operating in the viral disease diagnosis market are continuously focusing on technological advancements to meet the increasing demand for correct and rapid diagnosis of viral diseases.
Key players in the industry are heavily investing in research and development activities to improve the sensitivity, specificity, and cost-effectiveness of their diagnostic tests.
As a result, the viral disease diagnosis market competitive landscape is characterized by a high degree of competition, where prominent companies work to improve their market shares through innovative activities and strategic partnerships.
Roche Diagnostics, a Swiss multinational established in 1896, currently operates as a leader in the viral disease diagnosis market, providing molecular diagnostic, serological assays, and rapid tests for an extensive range of viruses.
In the past 125 years, Roche has been a pioneer in diagnostic technology, bringing the most sensitive and specific test to the market to allow the most effective disease control. Moreover, Roche has developed a significant distribution network and established a strong brand name, which is particularly notable in the HIV area.
Abbott Laboratories is another major competitor in the viral disease diagnosis market, focusing on the development of advanced diagnostics for infectious diseases.
The company produces rapid virus tests for HIV, Hepatitis, and influenza, ensuring that the products are affordable and accessible, which is particularly important in low-resource settings. Abbott is the largest division on the market, with a presence in over 100 countries worldwide.
Key Companies in the viral disease diagnosis market Include:
- InBios International
- Hologic
- Meridian Bioscience, Inc.
- Thermo Fisher Scientific
- Johnson Johnson
- Illumina, Inc.
- Abbott Laboratories
- Becton, Dickinson and Company
- Danaher
- Myriad Genetics
- QIAGEN
- Roche Diagnostics
- DiaSorin
- bioMérieux
- Cepheid
Viral Disease Diagnosis Market Developments
The market growth is attributed to the rising prevalence of viral diseases, technological advancements in diagnostic techniques, and increasing healthcare expenditure.
Recent news developments include the launch of rapid and point-of-care diagnostic tests for viral diseases, such as COVID-19 and influenza, to facilitate early detection and treatment.
Moreover, the development of multiplex assays and molecular diagnostics has enhanced the accuracy and speed of viral disease identification. Strategic collaborations between diagnostic companies and healthcare providers are also driving market expansion to improve patient outcomes and reduce healthcare costs.
Viral Disease Diagnosis Market Segmentation Insights
-
Viral Disease Diagnosis Market Disease Type Outlook
- HIV
- Hepatitis
- Influenza
- Respiratory Syncytial Virus (RSV)
- Cytomegalovirus (CMV)
- Epstein-Barr Virus (EBV)
- Herpes Simplex Virus (HSV)
-
Viral Disease Diagnosis Market Specimen Type Outlook
- Blood
- Urine
- Saliva
- Swabs
- Sputum
- Stool
-
Viral Disease Diagnosis Market Technology Outlook
- Nucleic Acid Amplification Tests (NAATs)
- Immunoassays
- Serology Tests
- Molecular Diagnostics
- Rapid Diagnostic Tests
-
Viral Disease Diagnosis Market Application Outlook
- Diagnostics
- Surveillance
- Treatment Monitoring
- Prognosis
-
Viral Disease Diagnosis Market End User Outlook
- Hospitals
- Clinics
- Laboratories
- Research Institutions
- Public Health Agencies
-
Viral Disease Diagnosis Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2023 |
8.87 (USD Billion) |
| Market Size 2024 |
9.37 (USD Billion) |
| Market Size 2032 |
14.69 (USD Billion) |
| Compound Annual Growth Rate (CAGR) |
5.78% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
InBios International, Hologic, Meridian Bioscience, Inc., Thermo Fisher Scientific, Johnson Johnson, Illumina, Inc., Abbott Laboratories, Becton, Dickinson and Company, Danaher, Myriad Genetics, QIAGEN, Roche Diagnostics, DiaSorin, bioMérieux, Cepheid |
| Segments Covered |
Disease Type, Specimen Type, Technology, Application, End User, Regional |
| Key Market Opportunities |
Point-of-care testing Molecular diagnostics Biosensors AI-powered diagnostics Companion diagnostics |
| Key Market Dynamics |
Rising prevalence of viral diseases Technological advancements in diagnostics Increasing awareness and accessibility to testing Availability of multiplex testing platforms Emergence of portable and point-of-care diagnostics |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Viral disease diagnosis market is expected to reach USD 67.66 billion by 2032, exhibiting a CAGR of 5.78% during the forecast period (2024-2032).
North America is expected to hold the largest market share in the Viral disease diagnosis market throughout the forecast period.
Rising prevalence of viral diseases, technological advancements in diagnostic techniques, and increasing healthcare expenditure are the key factors driving the growth of the market.
The hospital segment is expected to account for the largest share in the Viral disease diagnosis market due to the increasing number of viral disease cases and the presence of advanced diagnostic facilities in hospitals.
Key competitors in the Viral disease diagnosis market include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, and Siemens Healthineers.
The Asia-Pacific region is expected to witness a significant growth rate of 11.2% during the forecast period, owing to the increasing prevalence of viral diseases and the growing healthcare infrastructure in the region.
Challenges faced by the market include the high cost of diagnostic tests, the need for skilled professionals to operate diagnostic equipment, and the lack of access to diagnostic facilities in remote areas.
Opportunities for growth include the development of rapid and affordable diagnostic tests, the advancement of molecular diagnostic techniques, and the increasing awareness of viral diseases.
The COVID-19 pandemic has had a significant impact on the viral disease diagnosis market, leading to increased demand for diagnostic tests and the development of new diagnostic technologies.
Key trends include the integration of artificial intelligence (AI) into diagnostic systems, the development of point-of-care diagnostic devices, and the increasing use of non-invasive diagnostic techniques.
